Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 147 Carcinoma, Renal Cell 37 Parkinson Disease 4, Autosomal Dominant Lewy Body 31 Neoplasms 28 Cholangiocarcinoma 26 Endometrial Neoplasms 19 Thyroid Neoplasms 17 Liver Neoplasms 17 Melanoma 15 Stomach Neoplasms 13 Carcinoma, Non-Small-Cell Lung 13 Biliary Tract Neoplasms 13 Recurrence 9 Neoplasm Metastasis 9 Squamous Cell Carcinoma of Head and Neck 8 Ovarian Neoplasms 8 Breast Neoplasms 8 Uterine Cervical Neoplasms 7 Triple Negative Breast Neoplasms 5 Thyroid Carcinoma, Anaplastic 5 Small Cell Lung Carcinoma 5 Neuroendocrine Tumors 5 Esophageal Squamous Cell Carcinoma 5 Colorectal Neoplasms 5 Pancreatic Neoplasms 4 Kidney Neoplasms 4 Carcinoma, Transitional Cell 4 Carcinoma 4 Adenocarcinoma 4 Thyroid Cancer, Papillary 3

Interventions

Sorafenib 2 nimotuzumab 1 lenvatinib 1 atezolizumab 1 Tirapazamine 1 Stents 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HCC × lenvatinib × Clear all

NCT05873244 2025-03-21

CXD101 in Immunotherapy-related Liver Cancer

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡